[Form 4] Marker Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Marker Therapeutics director Steve Elms reported new stock option awards for board service. On 11/17/2025, he received stock options to buy 84,411 shares of common stock at an exercise price of $0.9548, representing remaining options for his 2024 director compensation under the 2020 Omnibus Stock Ownership Plan; 30,000 shares had previously been granted on February 12, 2025. On the same date, he also received options for 137,330 shares for his 2025 director service, also at $0.9548 per share. Both grants vest on the anniversary of the grant date and expire on 11/17/2035, and are held as direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ELMS STEVE

(Last) (First) (Middle)

C/O MARKER THERAPEUTICS, INC. 2450

HOLCOMBE BLVD, TMC PARTNERS OFFICE 1.311

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Marker Therapeutics, Inc. [ MRKR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.9548	11/17/2025		A		84,411(1)		(1)	11/17/2035	Common Stock	84,411	$0.00	84,411	D
Stock Option (right to buy)	$0.9548	11/17/2025		A		137,330(2)		(2)	11/17/2035	Common Stock	137,330	$0.00	137,330	D

Explanation of Responses:

1. Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.

2. Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.

	/s/ Julio C. Esquivel, as Attorney-in-Fact for Steve Elms	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Marker Therapeutics (MRKR) disclose in this Form 4 filing?

The filing reports that director Steve Elms received new stock option grants under Marker Therapeutics' 2020 Omnibus Stock Ownership Plan for his 2024 and 2025 board service.

How many stock options did MRKR director Steve Elms receive on 11/17/2025?

On 11/17/2025, he received options for 84,411 shares tied to 2024 service and 137,330 shares for 2025 service, both covering common stock.

What is the exercise price of the new Marker Therapeutics stock options?

The options reported in the filing have an exercise price of $0.9548 per share, equal to the closing price on November 17, 2025.

When do the new MRKR director stock options vest and expire?

Both 2024 and 2025 service-related option grants vest on the anniversary of the November 17, 2025 grant date and expire on 11/17/2035.

Under which plan were the Marker Therapeutics options to Steve Elms granted?

The options were granted under Marker Therapeutics' 2020 Omnibus Stock Ownership Plan as compensation for his service as a director.

How are Steve Elms' Marker Therapeutics stock options held?

The Form 4 indicates the options are held with direct ownership by Steve Elms.